Mark Hillman's BIIB Position Overview
Mark Hillman (via Hillman Capital Management, Inc.) currently holds 38.4K shares of Biogen Inc. (BIIB) worth $5.37 M, representing 3.13% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Mark Hillman has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 15.5K shares. Largest reduction occurred in Q3 2022, reducing 11.3K shares.
Analysis based on 13F filings available since 2013 Q2
Mark Hillman's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Mark Hillman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2019 | +18,115 | Add 0.00% | 18,114 | $296.73 |
| Q1 2020 | -1,734 | Reduce 9.57% | 16,380 | $316.36 |
| Q2 2020 | -134 | Reduce 0.82% | 16,246 | $267.57 |
| Q3 2020 | +3,391 | Add 20.87% | 19,637 | $283.70 |
| Q4 2020 | +292 | Add 1.49% | 19,929 | $244.87 |
| Q1 2021 | +7,360 | Add 36.93% | 27,289 | $279.75 |
| Q2 2021 | -50 | Reduce 0.18% | 27,239 | $346.27 |
| Q3 2021 | +1,050 | Add 3.85% | 28,289 | $282.97 |
| Q4 2021 | -1,098 | Reduce 3.88% | 27,191 | $239.90 |
| Q1 2022 | +15,488 | Add 56.96% | 42,679 | $210.60 |
| Q2 2022 | +340 | Add 0.80% | 43,019 | $203.96 |
| Q3 2022 | -11,265 | Reduce 26.19% | 31,754 | $267.02 |
| Q4 2022 | -1,678 | Reduce 5.28% | 30,076 | $276.92 |
| Q1 2023 | -540 | Reduce 1.80% | 29,536 | $278.03 |
| Q2 2023 | -125 | Reduce 0.42% | 29,411 | $284.85 |
| Q3 2023 | +4,895 | Add 16.64% | 34,306 | $257.01 |
| Q4 2023 | +170 | Add 0.50% | 34,476 | $258.77 |
| Q1 2024 | +1,316 | Add 3.82% | 35,792 | $215.63 |
| Q2 2024 | +162 | Add 0.45% | 35,954 | $231.82 |
| Q3 2024 | -701 | Reduce 1.95% | 35,253 | $193.84 |
| Q4 2024 | +7,813 | Add 22.16% | 43,066 | $152.92 |
| Q1 2025 | +959 | Add 2.23% | 44,025 | $136.84 |
| Q2 2025 | -2,053 | Reduce 4.66% | 41,972 | $125.59 |
| Q3 2025 | -3,618 | Reduce 8.62% | 38,354 | $140.08 |
Mark Hillman's Biogen Investment FAQs
Mark Hillman first purchased Biogen Inc. (BIIB) in Q4 2019, acquiring 18,114 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman has held Biogen Inc. (BIIB) for 24 quarters since Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman's largest addition to Biogen Inc. (BIIB) was in Q4 2019, adding 18,114 shares worth $5.38 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Mark Hillman's firm, Hillman Capital Management, Inc., owns 38,354 shares of Biogen Inc. (BIIB), valued at approximately $5.37 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Biogen Inc. (BIIB) represents approximately 3.13% of Mark Hillman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman's peak holding in Biogen Inc. (BIIB) was 44,025 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.